LINDA STEIMLING: Open Payments
NPI 1346358603 · PELLA, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$996 in 43 payments from 12 companies in 2025. Trend: 2023 $309 · 2024 $621 · 2025 $996
Food & beverage: $996
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $359 |
| ABBVIE INC. | 12 | $223 |
| Teva Pharmaceuticals USA, Inc. | 4 | $92 |
| E.R. Squibb & Sons, L.L.C. | 4 | $89 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $55 |
| Alkermes, Inc. | 1 | $31 |
| Janssen Pharmaceuticals, Inc | 1 | $29 |
| Neurocrine BioSciences, Inc. | 1 | $17 |
| MDD US Operations, LLC | 1 | $16 |
Products named: REXULTI, VRAYLAR, COBENFY, AUSTEDO XR, FANAPT, CAPLYTA, ARISTADA, INVEGA SUSTENNA.
Industry payments across IA — which companies pay providers there.
